Drug General Information
Drug ID	D0HK3N
Former ID	DIB009085
Drug Name	Belnacasan
Synonyms	Second generation ICE inhibitors, Vertex; VRT-043198; VRT-43198; VX-765; VX-765)
Drug Type	Small molecular drug
Indication	Epilepsy [ICD10:G40]		Phase 2	[526728]
Company	MedKoo Biosciences; vertex pharmaceuticals
Structure		Download 2D MOL 3D MOL
Formula	C24H33ClN4O6
Canonical SMILES	C1C(=O)O[C@H]([C@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O<br />)c1cc(c(cc1)N)Cl)C(C)(C)C)OCC
PubChem Compound ID	11398092
Target and Pathway
Target(s)	Interleukin-1 beta convertase	Target Info	Inhibitor	[527677], [528662]
KEGG Pathway	NOD-like receptor signaling pathway
	Cytosolic DNA-sensing pathway
	Amyotrophic lateral sclerosis (ALS)
	Salmonella infection
	Pertussis
	Legionellosis
	Influenza A
NetPath Pathway	TCR Signaling Pathway
	IL2 Signaling Pathway
	TGF_beta_Receptor Signaling Pathway
Pathway Interaction Database	IL1-mediated signaling events
	Direct p53 effectors
	IFN-gamma pathway
	Cellular roles of Anthrax toxin
Reactome	NOD1/2 Signaling Pathway
	Interleukin-1 processing
	The NLRP3 inflammasome
WikiPathways	MAPK Signaling Pathway
	Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
	Apoptosis
	Amyotrophic lateral sclerosis (ALS)
	Parkin-Ubiquitin Proteasomal System pathway
	Interleukin-1 processing
	Apoptosis Modulation and Signaling
	NOD pathway
References
Ref 526728	Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage. 2003 Oct;11(10):738-46.
Ref 527677	IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J Immunol. 2005 Aug 15;175(4):2630-4.
Ref 528662	(S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther. 2007 May;321(2):509-16. Epub 2007 Feb 8.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.